Polyanionic carbohydrate doxorubicin–dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations

Figures & data

Table 1 Mean hydrodynamic diameter, polydispersity index (PDI), and zeta potential of DOX-DS complexes containing DOX at the concentration of 0.05 mg/mL and different DS/DOX ratios

DS/DOX ratio (w/w)	Mean hydrodynamic diameter (nm)	PDI	Zeta potential (mV)
4:10	461 ± 31	0.257 ± 0.061	−19.5 ± 1.4
6:10	279 ± 28	0.29 ± 0.014	−33.2 ± 3.3

Figure 1 Effect of dextran sulfate/doxorubicin (DS/DOX) ratio on complexation efficiency of DOX-DS complexes.

Figure 2 A) Scanning electron micrographs of doxorubicin–dextran sulfate (DOX-DS) nanocomplexes (DOX: 60 μg/mL, DS/DOX [w/w]: 0.6), B) UV-visible spectrum of DOX-DS complex and free DOX, and C) fluorescence spectrum of DOX-DS complex and free DOX.

Figure 3 Effect of dextran sulfate/doxorubicin (DS/DOX) ratio on absorbance of DOX-DS complexes.

Figure 4 A) Effect of ethanol concentration, B) effect of NaCl concentration, and C) effect of polycationic chitosan (CS) on absorbance of doxorubicin–dextran sulfate (DOX-DS) nanocomplexes (DOX: 60 μg/mL, DS/DOX [w/w]: 0.6).

Figure 5 A) In vitro cumulative release and B) in vitro release rate of doxorubicin (DOX) from doxorubicin–dextran sulfate (DOX-DS) nanocomplexes (DOX: 60 μg/mL, DS/DOX [w/w]: 0.6) (n = 3). C) In vitro release of free DOX in phosphate buffer solution (pH 7.4), 37°C.

Figure 6 Isothermal titration calorimetry curve obtained from titration of 862 μM doxorubicin (DOX) with dextran sulfate (4797 μM glycosyl units) in (A) water (B) NaCl 0.15 M.

Figure 7 Chemical structure of doxorubicin.

Figure 8 Schematic illustration of doxorubicin–dextran sulfate nanocomplexation.